Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

43.05
+1.583.81%
Volume:274.40K
Turnover:11.76M
Market Cap:3.46B
PE:30.87
High:43.30
Open:42.01
Low:41.81
Close:41.47
52wk High:60.91
52wk Low:28.25
Shares:80.39M
Float Shares:78.97M
Volume Ratio:0.63
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.39
EPS(LYR):0.8200
ROE:8.77%
ROA:4.09%
PB:2.49
PE(LYR):52.50

Loading ...

Veracyte Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 30

Veracyte price target lowered to $45 from $50 at Guggenheim

TIPRANKS
·
Mar 30

Veracyte files initial beneficial ownership statement; Chief Dev and Tech Officer Kevin Richard Haas reports no securities beneficially owned

Reuters
·
Mar 26

Veracyte Appoints Kevin Haas as Chief Technology Leader

TIPRANKS
·
Mar 17

Veracyte Appoints Kevin Haas as Chief Development and Technology Officer

MT Newswires Live
·
Mar 17

Veracyte appoints Kevin Haas as chief development and technology officer

Reuters
·
Mar 17

Veracyte CEO Marc Stapley Reports Disposal of Common Shares

Reuters
·
Mar 07

Veracyte CFO Rebecca Chambers Disposes of Common Shares

Reuters
·
Mar 07

Veracyte SVP and General Counsel Annie McGuire Disposes of Common Shares

Reuters
·
Mar 07

Veracyte Is Maintained at Underweight by Morgan Stanley

Dow Jones
·
Mar 07

Morgan Stanley Lowers Price Target on Veracyte to $37 From $48, Keeps Underweight Rating

MT Newswires Live
·
Mar 06

Veracyte Chief Scientific and Medical Officer Phillip G. Febbo Disposes of Common Shares

Reuters
·
Mar 05

Veracyte Inc. Signals Durable Growth in Earnings Call

TIPRANKS
·
Mar 03

How Veracyte’s Profit Jump and 2026 Outlook Will Impact Veracyte (VCYT) Investors

Simply Wall St.
·
Mar 01

Veracyte (VCYT) Gets a Buy from Craig-Hallum

TIPRANKS
·
Feb 28

Stock Track | Veracyte Soars 7.81% Intraday Following Analyst Price Target Hike and Pipeline Updates

Stock Track
·
Feb 26

Needham Raises Price Target on Veracyte to $48 From $44, Keeps Buy Rating

MT Newswires Live
·
Feb 26

Veracyte’s ASCO Urology Data And TrueMRD Launch Test Investor Patience

Simply Wall St.
·
Feb 26

Veracyte Is Maintained at Buy by Needham

Dow Jones
·
Feb 26

Stock Track | Veracyte Soars 6.08% in Pre-market After Analyst Raises Price Target to $48

Stock Track
·
Feb 26